In this study the investigators wish to evaluate the efficacy, safety and tolerability of 160 ppm Nitric Oxide intermittently delivered via inhalation to subjects with Cystic Fibrosis (CF) infected with Non-tuberculosis mycobacteria (NTM), specifically with MABSC.